The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
Solventum purification and filtration portfolio expected to be highly complementary with Thermo Fisher’s bioproduction ...
As tariffs loom, 3M spinoff Solventum’s operating margins are continuing to shrink, and its investors are looking toward the company’s announced purification business sale for balance sheet relief.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback